76 results
DEFA14A
IMNM
Immunome, Inc.
26 Apr 24
Additional proxy soliciting materials
4:08pm
or her respective earlier death, resignation or removal. Nominees: 1a. Clay B. Siegall, Ph.D. For 1b. 1b. Carol Schafer For 2. To ratify, in a non
8-K
EX-10.1
oh8bh6l7 f7o
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-1.1
ig03y4jlm6
14 Feb 24
Other Events
4:11pm
424B5
9mjgtjlkhf
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
xrz 8hehozih53k8hx
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
EX-10.1
l5t lyik8cb1e4wm3
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
S-8
EX-99.4
707q2di wk
2 Feb 24
Registration of securities for employees
4:04pm
8-K
EX-10.1
8sd9nap
29 Dec 23
Departure of Directors or Certain Officers
5:00pm